Our findings suggest that liraglutide helps patients with obesity and BED by addressing both emotional and physical needs, reducing triggers, and decreasing food-related thoughts, which led to a decline in BED symptoms, aligning with previous research on GLP-1 analogs. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.